These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15229590)

  • 21. Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
    Heigener DF; Reck M
    Adv Ther; 2011 Feb; 28(2):126-33. PubMed ID: 21181318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 23. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
    Masago K; Fujita S; Irisa K; Kim YH; Ichikawa M; Mio T; Mishima M
    Jpn J Clin Oncol; 2010 Nov; 40(11):1105-9. PubMed ID: 20522446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
    Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
    J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
    [No Abstract]   [Full Text] [Related]  

  • 25. Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
    Benesova L; Pesek M; Belsanova B; Sekerka P; Minarik M
    J Sep Sci; 2010 Aug; 33(15):2349-55. PubMed ID: 20574956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
    Rai K; Fujiwara K; Tsushima M; Kudo K; Mizuta M; Matsuo K; Yonei T; Yamadori I; Kiura K; Sato T
    Jpn J Clin Oncol; 2011 Sep; 41(9):1138-41. PubMed ID: 21835826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 28. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
    Ku GY; Haaland BA; de Lima Lopes G
    Lung Cancer; 2011 Dec; 74(3):469-73. PubMed ID: 21565418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
    Twombly R
    J Natl Cancer Inst; 2005 Feb; 97(4):249-50. PubMed ID: 15713955
    [No Abstract]   [Full Text] [Related]  

  • 32. Translational research: the full cycle.
    Ledford H
    Nature; 2008 Jun; 453(7197):843-5. PubMed ID: 18548044
    [No Abstract]   [Full Text] [Related]  

  • 33. Look before you leap.
    Nat Med; 2004 Jun; 10(6):553. PubMed ID: 15170181
    [No Abstract]   [Full Text] [Related]  

  • 34. CSMD1 Mutation Related to Immunity Can Be Used as a Marker to Evaluate the Clinical Therapeutic Effect and Prognosis of Patients with Esophageal Cancer.
    Fan X; Song J; Fan Y; Li J; Chen Y; Zhu H; Zhang Z
    Int J Gen Med; 2021; 14():8689-8710. PubMed ID: 34849012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients.
    Shull AY; Clendenning ML; Ghoshal-Gupta S; Farrell CL; Vangapandu HV; Dudas L; Wilkerson BJ; Buckhaults PJ
    PLoS One; 2013; 8(3):e58731. PubMed ID: 23505554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
    Becker JC; Muller-Tidow C; Serve H; Domschke W; Pohle T
    World J Gastroenterol; 2006 Jun; 12(21):3297-305. PubMed ID: 16733844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Translation research: from accurate diagnosis to appropriate treatment.
    Webb CP; Pass HI
    J Transl Med; 2004 Oct; 2(1):35. PubMed ID: 15496233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer: understanding the target.
    Stratton MR; Futreal PA
    Nature; 2004 Jul; 430(6995):30. PubMed ID: 15229590
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
    Couzin J
    Science; 2004 Aug; 305(5688):1222-3. PubMed ID: 15333809
    [No Abstract]   [Full Text] [Related]  

  • 40. Medicine. Why a new cancer drug works well, in some patients.
    Marx J
    Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.